# Sperogenix Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sperogenix-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.sperogenix.com
- Latest round: Series B (Oct 27, 2023)
- Investors on record: 3

## About

Established in 2015 and based in Beijing, China, Sperogenix Therapeutics is a company focusing on the research, development and commercialization of new drugs for rare diseases in China, providing commercial development, clinical development and other businesses. Mr. Yan Zhiyu, the founder and CEO of the company, has been in the pharmaceutical industry for 28 years, and has held positions such as General Manager of Acetelon China and clinical work in the Department of Cardiology of Shanghai Zhongshan Hospital. In October 2023, it closed a round of series B funding.

The company develops rare disease drugs through commercial development and clinical development. Specifically, this includes introducing drug products for approval in China, collaborating with pharmaceutical companies to develop clinical drugs, and designing and implementing clinical trials that are applicable to China's regulatory requirements to launch the drugs. Specific products are available for the treatment of pulmonary hypertension, myasthenia gravis and other neurological and genetic metabolic diseases.

## Funding rounds

- Series B, Oct 27, 2023 — Lilly Asia Ventures, Prosperico Ventures
- Series A, May 10, 2019 — Lilly Asia Ventures, 5Y Capital

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Series B